drugset / Trial / NCT04516954
Convalescent Plasma for COVID-19 Patients
Phase 0
Completed
4 enrolled
Vinmec Research Institute of Stem Cell and Gene Technology
National Hospital for Tropical Diseases, Hanoi, Vietnam · collabNational Institute of Hematology and Blood Transfusion, Vietnam · collabNational Institute of Hygiene and Epidemiology, Vietnam · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in COVID19 patients who are in the medium stage. Supportive data exist for use of convalescent plasma in the treatment of COVID19 and other overwhelming viral illnesses. The study team wants to test the hypothesis that treatment with COVID19 CP will demonstrate salutary effects on COVID19 disease severity/duration, with the primary objective to reduce mortality. In addition, a major secondary objective to reduce the requirement for and/or duration of mechanical ventilation. The first phase is to test the safety of CP therapy.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2021-03-30
- Completion
- 2021-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Convalescent Plasma | Protein / enzyme biologic | 500 ml | Intravenous |